Nonalcoholic steatohepatitis (NASH) is quickly emerging as one of the most common reasons for both liver cirrhosis and liver transplant in the United States – soon predicted to overtake hepatitis C virus as the predominant etiology. Currently, there are no FDA-approved medications to treat these disorders. Hopefully, that will soon change.
Guest Author: Scott Malinowski, PharmD
Music by Good Talk